The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
Open accessAbstract
BACKGROUND: In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. METHODS: In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease. RESULTS: Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P<0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. CONCLUSIONS: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A large body of evidence indicates that statin-based strategies convey similar LDL-C lowering and relative cardiovascular risk reduction in patients with and those without T2DM.102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [442]
Experimental — accuracy not yet measuredIn the citing paper
“Although healthy lifestyle habits remain a cornerstone of T2DM management, trial data have confirmed the additional benefits of statin therapy in the primary and secondary prevention of CAD.13,102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD.22,180”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [22]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD. 368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9e45% in patients with CAD.368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“It was demonstrated in the REACH registry, a registry study on patients with ASCVD or overlapping risks factors for ASCVD, that approximately 16% registered cases are complicated with two or more ASCVD757).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [757]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
EUROASPIRE Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015136 · Cited by 665
Chen, Z., Peto, R., Collins, R., MacMahon, S. W., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537
Research works printed but not linked: 4
- Peto R, 1985, Circulation, 72, 451
- Keech A, 1992, Postgrad Med J, 68, 870
- 1994, Lancet, 344, 1383
- Keech A, 1998, Atherosclerosis, 136, S31
Cited by
Sorted by citations
Items 301–400 of 1,037
Reith, C. A., Baigent, C., Blackwell, L. S., Emberson, J., Spata, E., Davies, K., Halls, H. J., Holland, L., Wilson, K., Armitage, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01545-8 · Cited by 301
Ridker, P. M., & Torres, J. (2006) · JAMA · doi:10.1001/jama.295.19.2270 · Cited by 300
Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences
Rauch, U., Osende, J. I., Fuster, V., Badimón, J. J., Fayad, Z. A., & Chesebro, J. H. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-3-200102060-00014 · Cited by 300
Numbers needed to treat derived from meta-analyses---sometimes informative, usually misleading
Smeeth, L. L., Haines, A., & Ebrahim, S. B. J. (1999) · BMJ · doi:10.1136/bmj.318.7197.1548 · Cited by 299
Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure
Fukuta, H., Sane, D. C., Brucks, S., & Little, W. C. (2005) · Circulation · doi:10.1161/circulationaha.104.519876 · Cited by 298
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins
Shah, P. K., Kaul, S., Nilsson, J. Å., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4501.098468 · Cited by 298
McKinney, J. S., & Kostis, W. J. (2012) · Stroke · doi:10.1161/strokeaha.112.655894 · Cited by 294
Forrest, M. J., Bloomfield, D. M., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 293
Li, W., Wang, J., Thompson, P., Wong, S., Struthers, A. D., & MacDonald, T. M. (2002) · Heart · doi:10.1136/heart.88.3.229 · Cited by 293
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
Seliger, S. L., Weiss, N. S., Gillen, D. L., Kestenbaum, B. R., Ball, A., Sherrard, D. J., & Stehman‐Breen, C. O. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00109.x · Cited by 292
Koren, M. J., & Hunninghake, D. B. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.053 · Cited by 292
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, . (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 290
Young‐Xu, Y., Jabbour, S., Goldberg, R. J., Blatt, C. M., Graboys, T. B., Bilchik, B. Z., & Ravid, S. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.040 · Cited by 290
Graham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000277984.31558.c4 · Cited by 299
Tsuyuki, R. T. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1149 · Cited by 288
Current overview of statin-induced myopathy
Rosenson, R. S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.033 · Cited by 285
Zhao, X.-Q., Yuan, C., Hatsukami, T. S., Frechette, E. E. H. S., Kang, X.-J., Maravilla, K. R., & Brown, B. G. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1001.098463 · Cited by 284
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.028 · Cited by 282
Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis
Sillesen, H. H., Amarenco, P., Hennerici, M. G., Callahan, A., Goldstein, L. B., Zivin, J. A., Messig, M., & Welch, K. M. A. (2008) · Stroke · doi:10.1161/strokeaha.108.516450 · Cited by 277
Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Wilt, T. J., Bloomfield, H. E., MacDonald, R., Nelson, D., Rutks, I., Ho, M., Larsen, G., McCall, A., Pineros, S., & Sales, A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1427 · Cited by 275
Statin-related adverse events: A meta-analysis
Silva, M. A., Swanson, A. C., Gandhi, P. J., & Tataronis, G. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.005 · Cited by 275
Reduction of Stroke Events With Pravastatin
Byington, R. P., Davis, B. R., Plehn, J. F., White, H. D., Baker, J., Cobbe, S. M., & Shepherd, J. (2001) · Circulation · doi:10.1161/01.cir.103.3.387 · Cited by 275
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 275
Pedersen, T. R., Wilhelmsen, L., Færgeman, O., Strandberg, T. E., Þorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T. J., Haghfelt, T. H., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00910-3 · Cited by 274
Backer, G. D., Ambrosioni, E., Broch-Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/00149831-200312001-00001 · Cited by 273
Sundquist, J., & Winkleby, M. (2000) · International Journal of Epidemiology · doi:10.1093/ije/29.3.470 · Cited by 273
Katsimaglis, G., Danias, P. G., Danias, P. G., O'Neil-Callahan, K., Ryan, J. W., Mosby, C., Danias, P. G., Katsimaglis, G., Ioannidis, J. P. A., Ioannidis, J. P. A., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.048 · Cited by 272
Moghadasian, M. H., & Frohlich, J. J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00285-5 · Cited by 272
Charytan, D., & Kuntz, R. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001934 · Cited by 271
Drug Treatment of Hyperlipidemia in Women
Walsh, J. M. E. (2004) · JAMA · doi:10.1001/jama.291.18.2243 · Cited by 270
Alshehry, Z. H., Mundra, P. A., Barlow, C. K., Mellett, N. A., Wong, G., McConville, M. J., Simes, J. R., Tonkin, A., SULLIVAN, D. R., Barnes, E. H., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.023233 · Cited by 270
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E. M., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 269
Primary Prevention of Coronary Heart Disease
Grundy, S. M. (1999) · Circulation · doi:10.1161/01.cir.100.9.988 · Cited by 266
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., McInnes, G. T., Mehlsen, J., et al. (2001) · Journal of Hypertension · doi:10.1097/00004872-200106000-00020 · Cited by 266
Glaser, R., Selzer, F., Faxon, D. P., Laskey, W. K., Cohen, H. A., Slater, J. N., Detre, K. M., & Wilensky, R. L. (2004) · Circulation · doi:10.1161/01.cir.0000150335.01285.12 · Cited by 265
Statin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Hydrophilic or Lipophilic Statins?
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.687585 · Cited by 264
Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities
Rosenson, R. S. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00239-9 · Cited by 264
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s33 · Cited by 264
Beyond lipid lowering: the role of statins in vascular protection
Liao, J. K. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00195-x · Cited by 263
Statins are Associated with a Reduced Infrarenal Abdominal Aortic Aneurysm Growth
Schouten, O., van Laanen, J. H. H., Boersma, E. H., Vidaković, R., Feringa, H. H. H., Dunkelgrün, M., Bax, J. J., de Koning, J. J., van Urk, H., & Poldermans, D. (2006) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2005.12.024 · Cited by 263
Risk factor thresholds: their existence under scrutiny
Law, M. R., & Wald, N. J. (2002) · BMJ · doi:10.1136/bmj.324.7353.1570 · Cited by 263
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
Meneilly, G. S., & Tessier, D. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.1.m5 · Cited by 262
Jung, U. J., Kim, H. J., Lee, J. S., Lee, M. K., Kim, H. O., Park, E. J., Kim, H. J., Jeong, T., & Choi, M. (2003) · Clinical Nutrition · doi:10.1016/s0261-5614(03)00059-1 · Cited by 261
Matsuzaki, M., Kita, T., Mabuchi, H., Matsuzawa, Y., Nakaya, N., Oikawa, S., Saito, Y., Sasaki, J., Shimamoto, K., Itakura, H., et al. (2002) · Circulation Journal · doi:10.1253/circj.66.1087 · Cited by 260
Self-citationNikolsky, E., Aymong, E. D., Halkin, A., Grines, C. L., Cox, D. A., Garcı́a, E., Mehran, R., Tcheng, J. E., Griffin, J. J., Guagliumi, G., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.080 · Cited by 259
Low-density lipoprotein size and cardiovascular risk assessment
Rizzo, M., & Berneis, K. K. (2005) · QJM · doi:10.1093/qjmed/hci154 · Cited by 259
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Pasternak, R. C., Smith, S. C., Merz, C. N. B., Grundy, S. M., Cleeman, J. I., & Lenfant, C. J. M. (2002) · Stroke · doi:10.1161/01.str.0000034125.94759.41 · Cited by 257
Hobbs, R. F. (2002) · Family Practice · doi:10.1093/fampra/19.6.596 · Cited by 257
Koskinas, K. C., Siontis, G. C. M., Piccolo, R., Mavridis, D., Räber, L., Mach, F., & Windecker, S. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx566 · Cited by 257
Management of coronary artery disease: therapeutic options in patients with diabetes
Hammoud, T., Tanguay, J., & Bourassa, M. G. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00732-4 · Cited by 255
Zacco, A., Togo, J. A., Spence, K., Ellis, A., Lloyd, D., Furlong, S., & Piser, T. M. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11104.2003 · Cited by 255
A systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253
The lipid and non-lipid effects of statins
Wierzbicki, A. S., Poston, R. N., & Ferro, A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00055-x · Cited by 253
Diabetes‐associated macrovasculopathy: pathophysiology and pathogenesis
Rahman, S., Rahman, T., Ismail, A. A.-S., & Rashid, A. R. A. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00655.x · Cited by 251
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.1.213 · Cited by 251
Statin therapy and risk of dementia in the elderly
Li, G., Higdon, R., Kukull, W. A., Peskind, E. R., Moore, K. V. V., Tsuang, D. W., van Belle, G., McCormick, W. C., Bowen, J. D., Teri, L. L., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000142963.90204.58 · Cited by 250
Simes, R. J., Marschner, I. C., Hunt, D. U., Colquhoun, D. M., SULLIVAN, D. R., Stewart, R., Hague, W. E., KEECH, A. C., Thompson, P., White, H. D., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 250
Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics
Prosser, L. A., Stinnett, A. A., Goldman, P. A., Williams, L. W., Hunink, M. G. M., Goldman, L., & Weinstein, M. C. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00002 · Cited by 249
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
Lewis, J. H., Mortensen, M. E., Zweig, S., Fusco, M. J., Medoff, J. R., & Belder, R. (2007) · Hepatology · doi:10.1002/hep.21848 · Cited by 248
Chan, A. W., Bhatt, D. L., Chew, D. P., Quinn, M. J., Moliterno, D. J., Topol, E. J., & Ellis, S. G. (2002) · Circulation · doi:10.1161/hc0602.103586 · Cited by 248
Targeting tumor cell metabolism with statins
Clendening, J. W., & Penn, L. Z. (2012) · Oncogene · doi:10.1038/onc.2012.6 · Cited by 247
Cholesterol-Lowering Effect of a Theaflavin-Enriched Green Tea Extract
Maron, D. J., Lu, G. P., Cai, N. S., Wu, Z. G., Li, Y. H., Chen, H., Zhu, J. Q., Xue, J., Wouters, B. C., & Zhao, J. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.12.1448 · Cited by 246
Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E., & Jones, M. R. (2008) · Diabetes Care · doi:10.2337/dc08-0283 · Cited by 245
Das, U. N. (2008) · Lipids in Health and Disease · doi:10.1186/1476-511x-7-37 · Cited by 245
Taguchi, I., Iimuro, S., Iwata, H., Takashima, H., Abe, M., Amiya, E., Ogawa, T., Ozaki, Y., Sakuma, I., Nakagawa, Y., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032615 · Cited by 244
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
Alsheikh-Ali, A. A. A., Maddukuri, P. V., Han, H., & Karas, R. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.073 · Cited by 243
Long-term adherence with cardiovascular drug regimens
Kulkarni, S. P., Alexander, K. P., Lytle, B. L., HEISS, G. M., & Peterson, E. D. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.038 · Cited by 242
High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions
Barter, P. J., Kastelein, J. J. P., Nunn, A. V. W., & Hobbs, R. F. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00006-6 · Cited by 242
Tavazzi, L., Tognoni, G., Franzosi, M. G., Latini, R., Maggioni, A. P., Marchioli, R., Nicolosi, G. L., & Porcu, M. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.03.001 · Cited by 240
Safety and Tolerability of Pravastatin in Long-Term Clinical Trials
Pfeffer, M. A., KEECH, A. C., Sacks, F. M., Cobbe, S. M., Tonkin, A. M., Byington, R. P., Davis, B. R., Friedman, C. P., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000017634.00171.24 · Cited by 239
Managing Abnormal Blood Lipids
Fletcher, B. J., Berra, K. A., Ades, P., Braun, L. T., Burke, L. E., Durstine, J. L., Fair, J. M., Fletcher, G. F., Goff, D. C., Hayman, L. L., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169180 · Cited by 238
Bonovas, S., Filioussi, K., Tsavaris, N., & Sitaras, N. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7045 · Cited by 234
Herrington, D. M., Vittinghoff, E., Lin, F., Fong, J., Harris, F., Hunninghake, D. B., Bittner, V., Schrott, H. G., Blumenthal, R. S., & Levy, R. (2002) · Circulation · doi:10.1161/01.cir.0000019406.74017.b2 · Cited by 234
Statin therapy is associated with fewer deaths in patients with bacteraemia
Krüger, P., Fitzsimmons, K., Cook, D., Jones, M., & Nimmo, G. R. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2859-y · Cited by 233
Wolf, P. A. (2004) · Elsevier eBooks · doi:10.1016/b0-44-306600-0/50005-5 · Cited by 233
Whitney, E. J., Krasuski, R. A., Personius, B. E., Michalek, J. E., Maranian, A. M., Kolasa, M. W., Monick, E. A., Brown, B. G., & Gotto, A. M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-2-200501180-00008 · Cited by 233
Kuvin, J. T., Rämet, M. E., Patel, A. R., Pandian, N. G., Mendelsohn, M. E., & Karas, R. H. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123145 · Cited by 233
Kertai, M. D., Boersma, E. H., Westerhout, C. M., van Domburg, R., Klein, J., Bax, J. J., van Urk, H., & Poldermans, D. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.029 · Cited by 232
Statins Reduce the Risk of Lung Cancer in Humans
Khurana, V., Bejjanki, H. R., Caldito, G. C., & Owens, M. W. (2007) · CHEST Journal · doi:10.1378/chest.06-0931 · Cited by 232
2023 Chinese guideline for lipid management
Li, J., Zhao, S., Zhao, D. H., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 241
Ouchi, Y., Sasaki, J., Arai, H., Yokote, K., Harada, K., Katayama, Y., Urabe, T., Uchida, Y., Hayashi, M., Yokota, N., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039415 · Cited by 231
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 231
Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention
Laakso, M. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00789.x · Cited by 230
Eagle, K. A., Kline-Rogers, E. M., Goodman, S. G., Gurfinkel, E., Avezum, Á., Flather, M. D., Granger, C. B., Erickson, S. R., White, K., & Steg, P. G. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.041 · Cited by 230
Management of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 230
Goff, D. C., Gerstein, H. C., Ginsberg, H. N., Cushman, W. C., Margolis, K. L., Byington, R. P., Buse, J. B., Genuth, S., Probstfield, J. L., & Simons-Morton, D. G. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.002 · Cited by 229
Coronary Heart Disease: Reducing the Risk
Assmann, G., Cullen, P., Jossa, F., Lewis, B., & Mancini, M. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.8.1819 · Cited by 229
Statins and risk of cancer: A systematic review and metaanalysis
Browning, D., & Martin, R. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.22366 · Cited by 228
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction
Fonarow, G. C., French, W. J., Parsons, L. S., Sun, H., & Malmgren, J. A. (2001) · Circulation · doi:10.1161/01.cir.103.1.38 · Cited by 227
Hunt, D., Young, P., Simes, J., Hague, W., Mann, S., Owensby, D., Lane, G., Tonkin, A., & for the LIPID Investigators (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-10-200105150-00007 · Cited by 226
Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Kashiwagi, S., & Hayashi, J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01783-1 · Cited by 226
Metadata
- Authors
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-11-05
- Volume
- 339
- Issue
- 19
- Pages
- 1349-1357
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W38523360
- Cited by
- 5,261
- References
- 21
- Citations by year
- 2026: 19 · 2025: 24 · 2024: 57 · 2023: 53 · 2022: 60 · 2021: 58 · 2020: 72 · 2019: 82 · 2018: 81 · 2017: 94 · 2016: 114 · 2015: 111 · 2014: 118 · 2013: 167 · 2012: 147
- FWCI
- 312.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- pravastatin, coronary artery disease, statin therapy, cholesterol-lowering therapy, cardiovascular mortality, myocardial infarction, unstable angina, stroke, coronary revascularization, total cholesterol, secondary prevention, lipid-lowering diet
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Mortality, Myocardial Infarction, Risk, Incidence, Pravastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
